Impax Asset Management Group plc Sells 6,320 Shares of Illumina, Inc. (NASDAQ:ILMN)

Impax Asset Management Group plc lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,653 shares of the life sciences company’s stock after selling 6,320 shares during the quarter. Impax Asset Management Group plc’s holdings in Illumina were worth $7,704,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter worth about $32,000. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares in the last quarter. TD Private Client Wealth LLC boosted its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. V Square Quantitative Management LLC boosted its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its position in shares of Illumina by 73.5% during the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ILMN. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. Robert W. Baird upped their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. UBS Group upped their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Trading Down 0.3 %

Shares of ILMN stock opened at $93.96 on Tuesday. The company has a 50 day moving average of $126.97 and a 200-day moving average of $133.99. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $92.20 and a 12-month high of $156.66. The firm has a market cap of $14.88 billion, a P/E ratio of -12.23, a PEG ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.